Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZSDT regimen for BTK inhibitor–refractory mantle cell lymphoma
ChiCTR2500106604Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jul 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of hlx01, selinexor, dexamethasone and thalidomide in mantle cell lymphoma (MCL), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Complete response rate. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
hlx01selinexordexamethasonethalidomide
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on ChiCTR2500106604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106604.